<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833959</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-57641</org_study_id>
    <secondary_id>PANC0037</secondary_id>
    <nct_id>NCT04833959</nct_id>
  </id_info>
  <brief_title>Pilot Study of 89-Zr Panitumumab in Pancreas Cancer</brief_title>
  <official_title>Pilot Study of 89Zr Panitumumab in Pancreas Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular&#xD;
      imaging agent in patients with (metastatic) pancreas cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Business Decision&#xD;
  </why_stopped>
  <start_date type="Actual">March 26, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events assessed by CTCAE v5</measure>
    <time_frame>7 days</time_frame>
    <description>Safety is defined by the number of CTCAE v5 grade 2 or higher adverse events by Day 7 determined that are significant, definitely, probably or possibly related to 89Zr-panitumumab. Safety data will be summarized by grade, severity, and type.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>89Zr-Panitumumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be injected with 1 mCi (+/- 20%) of 89Zr-panitumumab followed by PET/CT imaging 4-7 days after study drug injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>89Zr-panitumumab</intervention_name>
    <description>Imaging Agent</description>
    <arm_group_label>89Zr-Panitumumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of pancreatic cancer.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive&#xD;
             heart failure (CHF); significant liver disease; or unstable angina within 6 months&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  History of infusion reactions to monoclonal antibody therapies.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
&#xD;
          -  Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide,&#xD;
             amiodarone, sotalol) antiarrhythmic agents.&#xD;
&#xD;
          -  Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.&#xD;
&#xD;
          -  Severe renal disease or anuria.&#xD;
&#xD;
          -  Known hypersensitivity to deferoxamine or any of its components.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrei Iagaru</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Universiy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 2, 2021</study_first_submitted>
  <study_first_submitted_qc>April 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

